Anavex Life Sciences (AVXL) Sinks on 2-73 Abstract Update
Tweet
Share
E-mailGet Alerts AVXL Hot Sheet
Join SI Premium – FREE
Anavex Life Sciences Corp. (NASDAQ: AVXL) is down 17.8% today after an abstract was updated on new exploratory Alzheimer drug ANAVEX 2-73 (below).
The infamous Martin Shkreli said the stock looks "worthless."
$AVXL looks worthless. Compound is uM for sigma receptor (meaningless affinity) and rest of muscarinic. Co. confused if its agonist or ant.
— Martin Shkreli (@MartinShkreli) November 5, 2015
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Weighs Tapping Musk For Equity Investment - Semafor
- Fastly, Inc. (FSLY) Climbs 10%
- PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
Create E-mail Alert Related Categories
FDA, Momentum Movers, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
